(Q41036925)

25 September 2017

1 reference

title

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal (English)

1 reference

25 September 2017

coronary artery disease

1 reference

T R Pedersen

1

1 reference

PubMed ID

8713485

25 September 2017

J A Tobert

series ordinal

2

1 reference

25 September 2017

1 January 1996

1 reference

25 September 2017

1 reference

25 September 2017

14

1 reference

25 September 2017

11-24

1 reference

25 September 2017

1

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-199614010-00003

25 September 2017

0 references

cites work

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin

1 reference

12 December 2020

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

1 reference

12 December 2020

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

A Comparison of the Tolerability and Efficacy of Lovastatin 20 mg and Fluvastatin 20 mg in the Treatment of Primary Hypercholesterolemia

1 reference

12 December 2020

Platelet function in hyperlipoproteinemia

1 reference

12 December 2020

Should there be a moratorium on the use of cholesterol lowering drugs?

1 reference

12 December 2020

Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group

1 reference

12 December 2020

Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia

1 reference

12 December 2020

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program

1 reference

12 December 2020

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study

1 reference

12 December 2020

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

1 reference

12 December 2020

Fluvastatin with and without niacin for hypercholesterolemia

1 reference

12 December 2020

Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries

1 reference

12 December 2020

Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Why sources of heterogeneity in meta-analysis should be investigated

1 reference

12 December 2020

Plasma protein binding displacement interactions--why are they still regarded as clinically important?

1 reference

12 December 2020

Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia

1 reference

12 December 2020

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

12 December 2020

President's page: expanding the role of the American College of Cardiology

1 reference

12 December 2020

Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants

1 reference

12 December 2020

Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)

1 reference

12 December 2020

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

12 December 2020

Long-term experience with pravastatin in clinical research trials

1 reference

12 December 2020

The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.

1 reference

12 December 2020

Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.

1 reference

12 December 2020

Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation

1 reference

12 December 2020

Scandinavian simvastatin study (4S)

1 reference

12 December 2020

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

1 reference

12 December 2020

Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations

1 reference

12 December 2020

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

12 December 2020

Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.

1 reference

12 December 2020

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

1 reference

12 December 2020

Lower patients' cholesterol now

1 reference

12 December 2020

Preventing heart attack and death in patients with coronary disease

1 reference

12 December 2020

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

1 reference

12 December 2020

Retardation and arrest of progression or regression of coronary artery disease: a review

1 reference

12 December 2020

ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collabor

1 reference

12 December 2020

The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

1 reference

12 December 2020

Prognostic significance of progression of coronary atherosclerosis

1 reference

12 December 2020

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

1 reference

12 December 2020

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

1 reference

12 December 2020

Lowering cholesterol levels in patients with coronary heart disease. The LIPID Study Management Committee

1 reference

12 December 2020

Effects of treatment with lovastatin and pravastatin on daytime cognitive performance.

1 reference

12 December 2020

Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.

1 reference

12 December 2020

Atherosclerosis: inhibition of regression as therapeutic possibilities

1 reference

12 December 2020

Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV

1 reference

12 December 2020

Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study

1 reference

12 December 2020

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

1 reference

12 December 2020

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

1 reference

12 December 2020

Doubts about preventing coronary heart disease

1 reference

12 December 2020

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

12 December 2020

Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)

1 reference

12 December 2020

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia

1 reference

12 December 2020

Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia

1 reference

12 December 2020

Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease

1 reference

12 December 2020

Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group

1 reference

12 December 2020

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

1 reference

12 December 2020

Lowering cholesterol with drugs and diet

1 reference

12 December 2020

Rhabdomyolysis associated with lovastatin and erythromycin use.

1 reference

12 December 2020

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

12 December 2020

A review of clinical trials comparing HMG-CoA reductase inhibitors

1 reference

12 December 2020

Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia.

1 reference

12 December 2020

Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers

1 reference

12 December 2020

Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole

1 reference

12 December 2020

Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

A Randomized Multicenter Trial Comparing and Efficacy of Simvastatin and Fluvastatin

1 reference

12 December 2020

Health policy on blood cholesterol. Time to change directions

1 reference

12 December 2020

Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations

1 reference

12 December 2020

The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolaemia. A double-blind, placebo-controlled, prospective study

1 reference

12 December 2020

Cholesterol lowering does have a role in secondary prevention

1 reference

12 December 2020

Cholesterol reduction yields clinical benefit. A new look at old data

1 reference

12 December 2020

Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients

1 reference

12 December 2020

Combination therapy with HMG CoA reductase inhibitors and gemfibrozil: practical or perilous?

1 reference

12 December 2020

Efficacy and long-term adverse effect pattern of lovastatin

1 reference

12 December 2020

Misleading meta-analysis

1 reference

12 December 2020

Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

1 reference

12 December 2020

The effects of pravastatin on hyperlipidemia in renal transplant recipients

1 reference

12 December 2020

Clinical experience with lovastatin.

1 reference

12 December 2020

Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group

1 reference

12 December 2020

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

12 December 2020

Controversies in meta-analysis: the case of the trials of serum cholesterol reduction

1 reference

12 December 2020

10.2165/00002018-199614010-00003

Identifiers

DOI

1 reference

PubMed ID

8713485

Dimensions Publication ID

25 September 2017

0 references

1 reference

PubMed ID

8713485